Immunogenicity of Enhanced Influenza Vaccines Against Mismatched Influenza Strains in Older Adults: A Review of Randomized Controlled Trials
Antigenic drift is a major driver of viral evolution and a primary reason why influenza
vaccines must be reformulated annually. Mismatch between vaccine and circulating viral …
vaccines must be reformulated annually. Mismatch between vaccine and circulating viral …
Comparative immunogenicity of enhanced seasonal influenza vaccines in older adults: a systematic review and meta-analysis
TWY Ng, BJ Cowling, HZ Gao… - The Journal of …, 2019 - academic.oup.com
Background A number of enhanced influenza vaccines have been developed for use in
older adults, including high-dose, MF59-adjuvanted, and intradermal vaccines. Methods We …
older adults, including high-dose, MF59-adjuvanted, and intradermal vaccines. Methods We …
Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial
BJ Cowling, RAPM Perera… - Clinical Infectious …, 2020 - academic.oup.com
Background Enhanced influenza vaccines may improve protection for older adults, but
comparative immunogenicity data are limited. Our objective was to examine immune …
comparative immunogenicity data are limited. Our objective was to examine immune …
[HTML][HTML] Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta …
JKH Lee, GKL Lam, T Shin, SI Samson, DP Greenberg… - Vaccine, 2021 - Elsevier
Background Influenza vaccine efficacy/effectiveness can vary from season to season due in
part to the dominant circulating strains and antigenic matching. This study reviews the …
part to the dominant circulating strains and antigenic matching. This study reviews the …
[HTML][HTML] Efficacy of recombinant influenza vaccine in adults 50 years of age or older
LM Dunkle, R Izikson, P Patriarca… - … England Journal of …, 2017 - Mass Medical Soc
Background Improved influenza vaccines are needed to control seasonal epidemics. This
trial compared the protective efficacy in older adults of a quadrivalent, recombinant influenza …
trial compared the protective efficacy in older adults of a quadrivalent, recombinant influenza …
A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age …
BD Forrest, AD Steele, L Hiemstra, R Rappaport… - Vaccine, 2011 - Elsevier
BACKGROUND: Although influenza is a major public health concern among adults≥ 60
years of age, few large, prospective studies of influenza vaccines have been conducted in …
years of age, few large, prospective studies of influenza vaccines have been conducted in …
Influenza A (H3N2) Antibody Responses to Standard-Dose Versus Enhanced Influenza Vaccine Immunogenicity in Older Adults and Prior Season's Vaccine Status
S Zhong, TWY Ng, DM Skowronski… - The Journal of …, 2024 - academic.oup.com
Background Annual influenza vaccination is recommended for older adults but repeated
vaccination with standard-dose influenza vaccine has been linked to reduced …
vaccination with standard-dose influenza vaccine has been linked to reduced …
Immunogenicity of adjuvanted versus high-dose inactivated influenza vaccines in older adults: a randomized clinical trial
KE Schmader, CK Liu, B Flannery, W Rountree… - Immunity & …, 2023 - Springer
Background Adjuvanted inactivated influenza vaccine (aIIV) and high-dose inactivated
influenza vaccine (HD-IIV) are US-licensed for adults aged≥ 65 years. This study compared …
influenza vaccine (HD-IIV) are US-licensed for adults aged≥ 65 years. This study compared …
A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly …
C Hatz, F von Sonnenburg, D Casula, M Lattanzi… - Vaccine, 2012 - Elsevier
BACKGROUND: Vaccines against pandemic A/H1N1 influenza are required to protect the
entire population. This dose range study aimed to identify priming antigen and adjuvant …
entire population. This dose range study aimed to identify priming antigen and adjuvant …
Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people …
S Pepin, JF Nicolas, H Szymanski… - Human Vaccines & …, 2021 - Taylor & Francis
ABSTRACT A quadrivalent high-dose inactivated influenza vaccine (IIV4-HD) is licensed for
adults≥ 65 y of age based on immunogenicity and efficacy studies. However, IIV4-HD has …
adults≥ 65 y of age based on immunogenicity and efficacy studies. However, IIV4-HD has …